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Alzheimer’s and Type 2 Diabetes are two of the most common 
diseases afflicting the elderly population today. A 2016 Report 
by the Alzheimer’s Association found that of the 5.4 million 
Americans with Alzheimer’s, an estimated 5.2 million people 
are age 65 and older (Alzheimer’s Association, 2014).  Similarly, 
the American Diabetes Association reported that in 2012, of 
the 29.1 million Americans with Diabetes, an estimated 11.8 
million people were age 65 and older (American Diabetes 
Association, 2012). The two conditions have traditionally been 
treated as independent disorders.  However, recent studies link-
ing Alzheimer’s to Type 2 Diabetes have led to the proposal that 
Alzheimer be referred to as “Type 3 Diabetes”. Discoveries of 
common pathological mechanisms between these two diseas-
es have given rise to novel clinical trials incorporating diabetes 
therapies to treat Alzheimer’s disease.
Methods
A variety of literary reviews and research papers on the subject 
were collected through use of the PubMed database. Keywords 
such as Alzheimer’s disease, insulin resistance and Type 2 Diabetes 
were used to search for relevant material. Access to PubMed was 
provided by the Touro College online library system.
Pathophysiology of Alzheimer’s and Type 2 
Diabetes
Alzheimer’s disease is a neurodegenerative condition, which 
results in nerve cell death and tissue loss throughout the brain 
(Li, Z et al., 2015).  Scans of brains of individuals suffering from 
Alzheimer’s demonstrate severe shrinkage of the hippocampus 
and cerebral cortex, as well as the enlargement of the ventricles 
(Querfurth et al., 2010).
The pathophysiology of Alzheimer’s disease is described by 
the amyloid cascade hypothesis. Cleavage of amyloid precur-
sor protein (APP) leads to the formation of the protein amy-
loid beta.  Excessive cleavage of APP coupled with inefficient 
removal of amyloid beta can lead to the formation of amyloid 
beta plaques in the brain.  These plaques damage and destroy 
brain cells by blocking cell-to-cell signaling at synapses (Reitz, 
2012). Amyloid beta plaques have also been shown to cause 
apoptosis.  The presence of amyloid plaques in the brain gener-
ates the production of harmful oxidative free radicals which in 
turn activates the c-Jun N-terminal kinase (JNK) pathway. The 
JNK pathway stimulates the transcription of several key target 
genes, including the death inducer Fas ligand. The binding of 
Fas ligand to its receptor Fas then induces a cascade of events 
that lead to caspase activation and ultimately neuronal cell 
death. (Yoshiyuki et al., 2001).
The tau protein also plays an important role in Alzheimer’s dis-
ease (Lasagna-Reeves CA et al., 2012). This protein is integral 
to maintenance of internal support and transport systems be-
tween brain cells. Hyperphosphorylation, which is the addition 
of phosphate to too many amino acids, leads to the collapse of 
tau proteins into twisted strands referred to as neurofibrillary 
tangles (Jack et al., 2013). Without the support of the tau pro-
tein, the transport system in the brain collapses. Consequently, 
essential nutrients are unable to reach brain cells and cell death 
ensues (Gong and Iqbal, 2008).
Diabetes is a metabolic disorder which develops when the body 
does not make enough insulin or is unable to use insulin effec-
tively. (Yarchoan and Arnold, 2014). If left untreated, diabetes can 
cause many complications, including kidney failure, diabetic ke-
toacidosis, heart disease and stroke (Schnell et al., 2016).  Type 
2 Diabetes is characterized by an insulin resistant state which 
is most commonly caused by obesity (Smith and Kahn, 2016). 
In insulin resistance, muscle, fat, and liver cells do not respond 
properly to insulin and thus cannot easily absorb glucose from 
the bloodstream. As a result, the body needs higher levels of 
insulin to help glucose enter cells. The pancreatic beta cells ini-
tially increase their insulin output but fail over time to keep up 
with the body’s increased demands for insulin. Type 2 diabetes 
develops when insulin production is inadequate to overcome 
insulin resistance, resulting in the drastic rise in blood glucose 
levels (Yarchoan and Arnold, 2014). 
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Discovery of Insulin Resistance in Alzheimer’s 
Disease
Insulin receptors are widely distributed in brain regions known to 
be involved in memory function, including the hippocampus, cere-
bral cortex and cerebellum (Werther et al., 2015).  Clinical studies 
have found evidence for central insulin resistance in Alzheimer’s 
brains. Post-mortem studies of brain tissues from people with 
Alzheimer’s disease have discovered extensive abnormalities in 
insulin and insulin-like growth factor signaling mechanisms in 
the brain (Steen et al., 2005).  A study of post-mortem human 
hippocampus Alzheimer’s tissue was done by exposing the tissue 
to different concentrations of insulin. This allowed researchers 
to study the activation of insulin pathways in the brain tissue of 
people with Alzheimer’s compared to the brain tissue of those 
with normal cognitive function. In normal brains, activation of 
the insulin receptor initiated a signaling cascade which led to the 
production of many downstream insulin signaling proteins. The 
blunted insulin response observed in the Alzheimer’s brain tissues 
was similar to the insulin resistance observed in Type 2 diabetes 
peripheral tissues (Talbot et al., 2012).
The formation of amyloid beta plaques has been implicated as 
a possible impetus for the removal of insulin receptors in brain 
cells.  Studies of Alzheimer’s brains have demonstrated that the 
binding of amyloid beta oligomers to hippocampal neurons trig-
gers the removal of dendritic insulin receptor substrates from 
the outer membrane of the cell (Xie et al., 2002). These studies 
prove that elevated amyloid beta levels induce the removal of cell 
surface insulin receptors, thereby furthering insulin resistance.
A molecular model has been proposed to explain how the am-
yloid beta plaques found in Alzheimer’s disease promote insulin 
resistance (Dineley et al., 2014).  This model is based on the in-
flammatory pathway observed in Type 2 Diabetes, where inflam-
matory cytokines play an important role in establishing insulin 
resistance.  Signaling from the inflammatory cytokine Tumor 
Necrosis Factor (TNF) stimulates JNK (Hoeks et al., 2012). 
Activation of the JNK pathway by TNF results in serine phos-
phorylation of the insulin receptor (Zhao et al., 2008). In order 
to be activated, phosphorylation of the insulin receptor must 
occur at a tyrosine residue.  Addition of the phosphate group at 
the serine amino acid in individuals with Type 2 Diabetes results 
in inhibition of the insulin receptor (Bomfim et al., 2012).
In a similar fashion, inflammatory cytokines induced by the pres-
ence of amyloid beta in the brain can lead to insulin resistance in 
Alzheimer’s.  Recent work suggests that soluble misfolded amy-
loid beta can induce inflammatory cytokines through an inflam-
matory pathway known as NF-κB-inducing kinase (NIK). The 
resulting inflammatory state induces insulin resistance through 
feedback inhibition of the insulin receptor (Carrero et al., 2012). 
In this case the many signaling chemicals produced by the in-
flammatory pathway stop the activity of the insulin receptor 
(Talbot et al., 2012).
Insulin resistance may promote Alzheimer pathology through 
several mechanisms.  Firstly, abnormal insulin signaling may 
promote amyloid beta and hyperphosphorylated tau formation 
through the kinase GSK-3.  The activity of GSK-3 is normally 
regulated through inhibition by the protein AKT, which is an im-
portant kinase in the insulin signaling cascade referred to as the 
IRS-1 –AKT pathway (Yarchoan and Arnold, 2014).  Therefore, 
dysfunctional insulin signaling caused by disturbances in the 
IRS-1 –AKT pathway leads to increased GSK-3 activity.  Studies 
of GSK-3 found that its activity increases tau protein phosphor-
ylation (Li, X et al., 2006) and that it is involved in amyloid beta 
production (Takashima, 2006).
Abnormal insulin signaling also interferes with memory and 
learning pathways.  Insulin is a direct regulator of the ERK/MAP 
kinase pathway.  This pathway is essential to the induction of 
longer term potentiation (LTP) and memory consolidation in 
the hippocampus (Winder 1999).   LTP is responsible for the 
maintenance of long term memory, which is the ability to recall 
episodes which are not part of the immediate past (Kelleher et 
al., 2004).  Disruptions of LTP and memory consolidation con-
tribute to the impaired cognitive function typified by Alzheimer’s 
disease (Dineley et al., 2014).
Discussion: New Role for Diabetes Drugs as a 
Treatment for Alzheimer’s
Given the role of insulin resistance and deficiency in the patho-
genesis of Alzheimer’s disease, it is possible that a drug current-
ly prescribed for Type 2 Diabetes may able also be useful for 
Alzheimer’s.  Various diabetes drugs are under study to test for 
their potential activity in Alzheimer’s.  This section provides an 
overview of the various clinical studies which assess the po-
tential prospects of using the diabetes drugs insulin and amylin, 
as well as the weight loss hormone leptin, to treat Alzheimer’s.
Insulin
The administration of exogenous insulin has predictably become 
a prime focus of the effort to treat insulin signaling dysfunction 
in Alzheimer’s.  Clinical trials have demonstrated that insulin ad-
ministration acutely affects behavior and cognitive performance 
in both healthy individuals and those suffering from Alzheimer’s. 
A 2001 study assessed the effects of peripherally administered 
insulin infusion in non-impaired individuals (Kern et al., 2001). 
Two groups were infused with insulin for 6 hours, one at a high 
rate and the other at a low rate. Any effects of the insulin ad-
ministration on blood glucose concentrations were counteract-
ed by constant glucose infusions.  Comparison of the results 
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of the high rate insulin and low rate insulin treatment groups 
indicated an improvement in the cognitive function of the high 
rate insulin group.  Subjects exposed to higher insulin infusion 
rates demonstrated changes in auditory-evoked potentials, had 
enhanced memory as evidenced by improved word recall and 
improved cognitive flexibility as measured by the Stroop test. 
Similar benefits of peripheral insulin administration on cogni-
tive function were observed in individuals with Alzheimer’s. In a 
1999 study, Alzheimer’s patients showed improved story recall 
and attention during insulin infusion relative to saline infusion 
(Craft et al.,2012).
Despite the results of these clinical trials, there are two main 
concerns that must be addressed with regards to utilizing pe-
ripheral insulin administration as a treatment for Alzheimer’s. 
Firstly, peripherally administered insulin cannot bypass the blood 
brain barrier in order to enter the central nervous system (CNS) 
and is therefore unable to affect and improve brain function. 
Secondly, peripheral insulin infusions can induce hypoglycemia. 
Hypoglycemia is a condition characterized by abnormally low 
blood glucose which can lead to a seizure or unconsciousness 
if left untreated. Although hypoglycemia was mitigated by simul-
taneous glucose infusions in both studies involving peripheral 
insulin administration, this solution is highly impractical outside of 
a research setting (Yarchoan and Arnold, 2014).
In light of these concerns, intranasal insulin is considered to be 
the best method for insulin delivery in Alzheimer clinical trials. 
Insulin that is delivered nasally bypasses the blood brain barrier 
and is rapidly delivered into the cerebrospinal fluid from where 
it can easily enter the CNS (Mao et al., 2016).  Additionally, be-
cause intranasal insulin is preferentially delivered to the CNS, it 
is possible to achieve clinically relevant insulin concentrations 
in the CNS without causing systemic hypoglycemia (Yarchoan 
and Arnold, 2014).
Pilot clinical trials using intranasal insulin have had successful re-
sults. A 2008 clinical trial reported that delivery of intranasal insulin 
for 21 days improved story recall, attention and caregiver-rated 
functional status in cognitively impaired subjects or individuals with 
Alzheimer’s (Reger et al., 2008). In another clinical trial subjects 
given insulin spray over a placebo demonstrated improved delayed 
memory and cognitive function (Craft et al., 2012). 
One study sought to illustrate the underlying mechanisms 
through which intranasal insulin ameliorates Alzheimer’s pathol-
ogy (Mao et al., 2016).  APP/PS1 mice possessing the patholog-
ical features of Alzheimer’s disease received intranasal insulin 
treatments for a total of 6 weeks, while a control group re-
ceived saline treatments. Tissue samples were harvested from 
both groups upon the conclusion of the treatment period.  
In order to determine whether intranasal insulin enhances brain 
insulin signaling, the respective levels of key components of the 
insulin signaling pathway, such as the insulin receptor beta-sub-
unit (IRB) and protein B kinase (AKT), were measured through 
Western Blot analysis.    Tissue from healthy wild type mice was 
also analyzed to serve as a reference marker of normal levels. 
The total levels of IRB and AKT were significantly decreased 
in the saline treated APP/PS1 mice compared with wild-type 
controls. However, the levels of IRB and AKT in the mice which 
received intranasal treatment were closer that of the wild-type 
mice, indicating that intranasal insulin treatment can partially 
protect APP/PS1 mice from brain insulin signaling deficits.
Intranasal insulin was also shown to reduce the activation of 
JNK in APP/PS1 mice.  Activation of the JNK pathway results 
in serine phosphorylation of the insulin receptor and induces 
apoptosis.  The level of phosphorylation of JNK was significantly 
increased in the hippocampus of saline-treated mice compared 
with wild-type controls, signifying that intranasal insulin reduces 
JNK activation.  
Immunohistochemical analysis of the tissue samples measured 
the amounts of amyloid beta plaque deposits in the brains of 
the APP/PS1 mice.  The number of amyloid plaques in the APP/
PS1 insulin-treated mice was significantly reduced in both the 
hippocampus and cortex compared to the saline control group. 
It was also discovered that the area of amyloid beta plaques 
was significantly decreased in both the hippocampus and cortex 
of the insulin treated mice.  Additionally, quantitative analysis 
revealed substantially reduced soluble amyloid beta oligomers 
in insulin-treated APP/PS1 mice.  This revelation is especial-
ly significant considering that soluble amyloid beta oligomers 
are considered the most neurotoxic form of amyloid beta. 
Enhanced neurogenesis was also observed in the insulin-treated 
APP/PS1 mice. It was shown that intranasal insulin significantly 
increased levels of DCX, a marker of neurogenesis.  The overall 
conclusions of the study were that intranasal insulin treatment 
improves cognitive deficits, ameliorates defective brain insulin 
signaling, strongly reduces amyloid beta plaque formation, inhib-
its JNK activation and promotes neurogenesis in APP/PS1 mice.
Despite the successful results observed in studies involving 
intranasal insulin treatment, there is concern that chronic hy-
perinsulinemic conditions in the brain may actually promote 
brain insulin resistance.  Excessive exposure to insulin in mice 
has been shown to lead to abnormal phosphorylation of key 
components of the insulin signaling pathway, such as AKT and 
GSK-3, in a manner consistent with insulin resistance (Kim et 
al., 2011).  It may therefore be beneficial to explore avenues 
of diabetes treatments which restore the byproducts of insulin 




Amylin is a metabolic hormone which is co-secreted with insu-
lin by pancreatic beta cells (Adler et al., 2014). Amylin’s systemic 
effects in diabetic patients include the lowering of blood glucose 
levels through delayed gastric emptying, increased satiety, and 
decreased secretion of glucagon, which is an antagonist of insu-
lin (Yarchoan and Arnold, 2014).  
Amylin’s signaling activity has the potential to alleviate the 
detrimental effects of insulin resistance in Alzheimer’s dis-
ease. Amylin binds to independent receptors in the brain to 
activate signaling pathways that converge with insulin signaling. 
Amylin activates the production of the protein AKT, which is 
needed for the proper regulation of GSK-3, a protein which 
can lead to increased production of amyloid beta plaques and 
hyper phosphorylated tau (Moon et al., 2011).  Amylin is also 
a known modulator of the ERK signaling cascade, a pathway 
significant in the maintenance of long term memory and mem-
ory consolidation (Adler et al., 2014).  An advantage of using 
amylin as a medication is that it poses no risk of hyperinsulin-
emia, as it can activate the insulin pathway without interfering 
with the concentration of insulin in the body (Yarchoan and 
Arnold, 2014).  
One study investigated the potential outcomes of using amylin 
as a treatment for Alzheimer’s.  The first part of the study com-
pared plasma human amylin levels between individuals with 
Alzheimer’s or mild cognitive impairment and individuals with no 
cognitive impairments (Adler et al., 2014).  The results showed 
significantly lower amylin levels among subject with Alzheimer’s 
and mild cognitive impairments compared to individuals with no 
cognitive deficits.  With this correlation between amylin levels 
and cognitive function established, a follow-up study was con-
ducted in order to investigate the effects of amylin administra-
tion on Alzheimer’s pathology.  A senescence-accelerated prone 
(SAMP8) mouse was selected as a model of Alzheimer’s related 
dementia, because it displays multiple features known to occur 
early in the pathogenesis of Alzheimer’s including cortical atro-
phy, amyloid beta alterations, tau phosphorylation and severe 
deficits of learning and memory.  The SAMP8 mice were treated 
with either amylin or saline infusions for a total of 5 weeks.  Due 
to the tendency of amylin to aggregate into brain plaques in its 
natural form, a soluble analog of amylin called pramlintide was 
used in the study.  
The object recognition test was performed on the mice during 
the last week of the 5-week treatment period in order to assess 
the effects of amylin on cognitive function. The object recog-
nition test is a behavioral assay that is based upon the natural 
tendency of mice to investigate a novel object instead of a fa-
miliar one, as well as their innate tendency to restart exploring 
when they are presented with a novel environment.  The mice 
were placed in an open field box filled with different objects of 
various shapes and sizes.  After a series of trials, during which 
the mice habituated to the configuration and properties of 
the different objects, some of the objects were replaced with 
new ones to evaluate novel object recognition.  The pramlin-
tide-treated SAMP8 mice spent a greater proportion of time 
exploring the novel objects as compared with the familiar ob-
jects, whereas the saline-treated SAMP8 mice did not differ in 
time spent with the novel and familiar objects.  The behavior of 
the pramlintide-treated mice signified a marked improvement in 
their cognitive function.
Hippocampal tissue samples were harvested from the SAMP8 
mice in order to assess the effect of amylin on oxidative 
stress, an important pathologic feature of Alzheimer’s.  The 
protein levels found in the pramlintide-treated SAMP8 mice 
indicated a decrease in the molecular markers associated 
with oxidative stress and neuro-inflammation.  The pramlin-
tide-treated SAMP8 mice had significantly decreased expres-
sion of the protein H0-1 in the hippocampus compared with 
saline-treated mice.  HO-1 is a cellular stress protein that is 
activated during high oxidative stress and inflammatory states, 
and is also known to be increased in the cerebral cortex of 
Alzheimer’s brains.  The pramlintide-treated SAMP8 mice also 
had decreased levels of the lipid peroxidation adduct HNE 
and the enzyme COX-2.  HNE is a protein that is known to 
be an early and abundant cellular stress marker in Alzheimer’s 
brains, while C0X-2 is a classic marker of inflammation which 
is increased in Alzheimer’s brains.
The pramlintide-treated SAMP8 mice expressed high amount of 
proteins associated with synaptic activity and dendritic growth. 
Amylin was found to increase expression of hippocampal syn-
apsin I, a protein located in neuronal synaptic vesicles that is 
involved in synapse formation, neurotransmitter release, and 
learning and memory.  A robust increase in CDK5 was also ob-
served in the hippocampus of the pramlintide-treated SAMP8 
mice. CDK5 is a kinase which plays an intimate role in synaptic 
plasticity, learning and memory in adult brains. 
The overall conclusions of the study were that chronic infusion 
of amylin in SAMP8 mice was found to improve memory per-
formance in object recognition tests, increase neural synaptic 
activity and decrease inflammatory markers in the hippocam-
pus. Amylin treatment improved both the cognitive status and 
Alzheimer’s pathology features of the SAMP8 mice.  
Another study also assessed the results of amyloid treatment 
on behavioral impairment and brain amyloid pathology in 
mouse models of Alzheimer’s disease (Zhu et al., 2015). The 
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study utilized 5XFAD Alzheimer mice which exhibit significant 
neuron loss.  The 5XFAD mice were treated with intraperito-
neal injections of either pramlintide or saline once daily for 10 
weeks.
The 5XFAD mice were tested for improvements in cognitive 
functions by going through a Morris water maze.  The Morris 
water maze test is used to determine hippocampal spatial 
memory deficits.  The test consisted of placing the rodent in a 
circular tank filled with cloudy water, which is used to motivate 
the animal to escape the water by swimming to a hidden plat-
form located in one quadrant of the pool. Over several days the 
rodent learnt to find the hidden platform by using spatial cues, 
such as posters or taped objects strategically placed on the walls 
outside of the water maze, in the testing room.  The pramlintide 
treatment improved the performance of the mice in the Morris 
water maze test, reducing the time necessary for memory ac-
quisition and retention during maze training as compared to 
the saline-treated control group.  The improved performance of 
the pramlintide-treated groups over the saline-treated groups 
in the Morris water maze test demonstrated that peripheral 
treatments with pramlintide improves learning and memory in 
the 5XFAD mice.
Pramlintide treatment was shown to have an effect on amy-
loid beta levels, one of the prime pathological hallmarks of 
Alzheimer’s. Immunoassays of brain tissue from the 5XFAD 
mice revealed that pramlintide-treated 5XFAD mice experience 
a reduction in both size and intensity of amyloid beta plaques 
in the cortex, hippocampus and thalamus and had decreased 
numbers of amyloid beta plaques in all areas of the brain with 
the exception of the hippocampus. Furthermore, comparison 
of amyloid beta serum levels from before and after the intra-
peritoneal pramlintide infusion revealed a significant increase in 
serum amyloid beta after the infusion.  These results indicate 
that pramlintide enhances the removal of amyloid beta from the 
brain and its transfer into the blood. 
The successful outcomes of these separate studies assessing the 
effect of pramlintide treatment on different Alzheimer’s mouse 
models indicate that amylin has potential to become a promis-
ing new avenue for the treatment of Alzheimer’s.  Amylin was 
shown to improve cognitive function, reduce oxidative stress 
markers, increase synaptic activity and enhance clearance of am-
yloid beta from the brain.
Leptin
Leptin is a chemical produced by fat tissues which activates the 
central nervous system to regulate food consumption and en-
ergy expenditure (Oomura et al., 2006). Although leptin has tra-
ditionally been studied in the context of obesity, recent studies 
have examined its neurological effects.  Leptin receptors are 
highly expressed in areas of the brain that are involved in learn-
ing and memory, such as the hippocampus (Li, X-L et al., 2002).  
A study was designed in order to assess leptin’s role in the 
regulation of hippocampal functions and the control of learn-
ing and memory processes (Li, X-L et al., 2002).    The study 
focused on leptin receptor-deficient mice.  The behavioral 
and molecular data obtained from the leptin receptor-defi-
cient mice was compared against a positive leptin receptor 
control group.  Both groups of mice were put through the 
Morris water maze task.  The leptin receptor-deficient mice 
swam greater distance than their positive controls before 
they found and climbed onto the hidden platform.  When 
the platform was removed, the leptin receptor-deficient mice 
crossed the original platform location fewer times than the 
positive control group. The hippocampus was removed from 
the leptin receptor-deficient rodents and the control group. 
Electrophysiological analysis of the hippocampal tissue of the 
leptin receptor-deficient mice showed impairments of long 
term potentiation (LTP) and long term depression (LTD).  The 
decreased cognitive behavior and impaired LTP and LTD pro-
cessing observed in the leptin receptor-deficient mice support 
the conclusion that leptin enhances LTP and regulates mecha-
nism involved in both learning and memory 
Leptin also appears to regulate a number of defining features 
of Alzheimer’s disease.  AMP- dependent kinase (AMPK) is 
known to regulate glycogen synthase kinase-3B (GSK-3B), a 
kinase which is crucial in the regulation of tau phosphorylation 
(Nikolaos et al., 2009).  It has been shown that leptin directly 
activates AMPK and thereby possesses the ability to modulate 
tau phosphorylation (Yu et al., 2004).  Leptin also facilitates the 
uptake of amyloid beta complexes via its regulation of the lipo-
protein receptor-like protein (Fewlass et al., 2004).  Thus, leptin’s 
activity directly affects the regulation of amyloid beta uptake 
and tau phosphorylation, two of the impaired pathophysiological 
features of Alzheimer’s disease. 
One study assessed the effects of leptin treatment on CRND8 
Alzheimer’s mouse models (Greco et al., 2010). The CRND8 
mice received daily treatments of leptin for a total of 8 weeks 
with a control group receiving saline infusions.  Leptin-treated 
mice spent statistically more time with the novel object com-
pared to the saline-treated control group during the object 
recognition test, indicating an improvement in working memory 
performance after leptin treatment.  Analysis of brain tissue from 
the CRND8 mice revealed that the leptin-treated group had 
reduced  amyloid beta levels in both brain and serum.  Staining 
of the brain tissue for amyloid fibers showed a significant de-
crease in amyloid burden in the hippocampus of the leptin 
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treated CRND8 mice, which was associated with a decrease 
in the average size of amyloid plaques.  There was no significant 
increase in the levels of the inflammatory molecule C-reactive 
protein, tumor necrosis factor or cortisol in the plasma of the 
leptin-treated group compared to the saline-treated group, in-
dicating that leptin does not induce an inflammatory reaction. 
The results of the study fully support the ability of leptin to 
ameliorate Alzheimer’s like pathological pathways, strengthening 
leptin’s potential of becoming a novel therapeutic treatment for 
Alzheimer’s disease.
Synergistic Effects of Amylin and Leptin
Leptin and amylin activate overlapping signaling cascades and 
ultimately converge on the insulin signaling pathway by activat-
ing AKT and increasing insulin sensitivity (Yarchoan and Arnold, 
2014). Recent studies have indicated that leptin and amylin sig-
naling appear to have synergistic properties.  
One study profiled hypothalamic neurons in order to deter-
mine the effects of amylin and leptin on hypothalamic activity (Li, 
Z et al., 2015).  It was discovered that hypothalamic expression 
of lapp, a precursor to amylin, was markedly decreased in mice 
with mutations in the gene regulating the production of amylin, 
but was normalized after infusions of leptin. The decrease of 
amylin expression in mice that had mutated leptin genes showed 
that hypothalamic amylin is a neuropeptide that is leptin regulat-
ed.  Additionally, AC187, an amylin antagonist, was found to blunt 
the activity of leptin and decreased its effects on neurons in the 
hypothalamus.  The presence of the amylin antagonist signifi-
cantly inhibited the effects of leptin on both leptin depolarizing 
and hyperpolarizing neurons.  The ability of an amylin antago-
nist to blunt the response of leptin suggests that amylin can 
modulate leptin’s effects.  Leptin and amylin were also found to 
have synergistic effects on hypothalamic neurons.  Patch clamp 
recordings demonstrated that the presence of either leptin or 
amylin elicited similar excitatory and inhibitory effects on hy-
pothalamic neurons.  Leptin excited 65% and inhibited 35% of 
the neurons, while amylin excited 62% and inhibited 38%.  The 
significant correlation between the effects of individual neurons 
exposed to both treatments indicates that amylin depolarizes 
the same neurons that are depolarized by leptin and hyperpo-
larizes the same neurons that are hyperpolarized by leptin. This 
suggests that the response of the neuron would be amplified 
upon simultaneous presentation of amylin and leptin.  
The synergistic potential of these two treatments has been 
explored with regards to treating obesity.  Stand-alone obesi-
ty treatments have proven unsuccessful because diet-induced 
obese (DIO) rats and obese humans are only minimally respon-
sive to even high pharmacological doses. Nonetheless, amylin 
possesses the ability to heighten leptin’s effects.  For this reason, 
one study found that doses of exogenous leptin that was high-
ly effective in lean rats had minimal effects on weight or food 
intake in DIO rats.  However, the results of the study showed 
that administration of amylin together with leptin resulted in a 
synergistic, fat-specific reduction in body weight in two inde-
pendent experiments (Roth et al., 2008). 
In light of this discovery, a clinical trial was designed in order to 
evaluate the weight-lowering effect of combined amylin/leptin 
(using pramlintide/mertreleptin) treatment in human obesity. 
A 24-week, randomized, double-blind, study was conducted in 
obese or overweight subjects. Subjects receiving pramlintide/
metreleptin lost almost 13% of their initial body weight over 
24 weeks, compared with only ~8% in subjects receiving ei-
ther pramlintide or metreleptin. Towards the end of the study, 
weight loss plateaued in subjects treated with monotherapy, 
but not in subjects treated with the combination. The overall 
results of the study showed that weight loss caused by the 
combination of leptin and amylin in humans was greater than 
the additive weight loss of each drug used alone (Ravussin et 
al., 2009).  
Thus far, there have been no studies to examine the efficacy of 
combination therapy of leptin and amylin to treat Alzheimer’s. 
The successful results observed in weight loss clinical trials sug-
gest that even greater improvements in memory in Alzheimer’s 
patients may be possible by using amylin and leptin as a com-
bined therapy.  
Conclusion
The discovery of insulin resistance in Alzheimer’s has given 
way to a growing interest in restoring insulin signaling in 
Alzheimer’s with therapeutic agents originally developed for 
the treatment of Type 2 Diabetes.  Intranasal insulin, amylin 
and leptin are examples of hormones typically associated with 
obesity and diabetes which have shown promise for treating 
Alzheimer’s disease.  An advantage of using amylin and leptin 
as medications for Alzheimer’s is that unlike with insulin, treat-
ment using these hormones pose no risk of inducing hyperin-
sulinemia, as they activate the products of the insulin signaling 
pathway without interfering with the concentration of insulin 
in the body.  Furthermore, weight loss studies have discovered 
that amylin and leptin are synergistic substances which pro-
duce significantly enhanced results when used in combination. 
This unique synergy suggests that achieving even greater im-
provements in memory may be possible by using amylin and 
leptin as a combined therapy for Alzheimer’s.  Further research 
will need to take place before the proposed combined therapy 
can be tested in a clinical trial and ultimately be distributed 
pharmaceutically. 
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